1 recruiting, 1 terminated. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow epalrestat: new trials by email Literature Review of epalrestat trials Research Report on epalrestat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy. Nebivolol+ Standard care arm, Epalrestat + Alpha Lipoic Acid +Standard care, Standard care alone - Diabetic Neuropathy Peripheral | Phase 2 / Phase 3 | Recruiting | St. John's Research Institute | 120 | 2024-11-15 | 2025-02-04 |
| Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG Epalrestat, Placebo - Pmm2-CDG, Phosphomannomutase 2 Deficiency | Phase 3 | Terminated | Maggie's Pearl, LLC | 42 | 2022-11-10 | 2025-09-25 |
Congenital disorder of glycosylation type 1A (1)
Maggie's Pearl, LLC (1) · St. John's Research Institute (1)
India (1) · United States (1)